Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669570 | 0.87 | GRM1 (0.50) | GRM1BACE1ALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL13488532 | 0.81 | GPR55 (0.43) | PTGESGPBAR1CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL8077531 | 0.78 | ALDH1A1 (0.41) | GRM1ALDH1A1GFERKDM4ETSHR | |
| SCHEMBL8078111 | 0.78 | ALDH1A1 (0.44) | GRM1ALDH1A1GFERKDM4EL3MBTL1 | |
| SCHEMBL8151067 | 0.78 | ALDH1A1 (0.46) | GRM1ALDH1A1GFERKDM4EL3MBTL1 | |
| SCHEMBL31571087 | 0.78 | ALDH1A1 (0.44) | GRM1ALDH1A1GFERKDM4EL3MBTL1 | |
| SCHEMBL31571103 | 0.78 | ALDH1A1 (0.41) | GRM1ALDH1A1GFERKDM4ETSHR | |
| SCHEMBL10919184 | 0.78 | ALDH1A1 (0.50) | GRM1ALDH1A1KDM4EL3MBTL1TSHR | |
| SCHEMBL13230262 | 0.78 | BACE1 (0.43) | BACE1ALDH1A1KDM4EPTGESCYP1A2 | |
| SCHEMBL379575 | 0.78 | BACE1 (0.43) | BACE1L3MBTL1PTGESCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | GRM1 3999/4885BACE1 2560/4885ALDH1A1 2041/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | GRM1 3999/4885BACE1 2560/4885ALDH1A1 2041/4885 |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | GRM1 3148/4885BACE1 2438/4885ALDH1A1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.